Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics (ATXS)
NASDAQ:ATXS
Holding ATXS?
Track your performance easily
ATXS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.26 - $16.90
Previous Close$11.82
Volume148.10K
Average Volume (3M)323.40K
Market Cap
$666.95M
Enterprise Value$318.03M
Total Cash (Recent Filing)$354.70M
Total Debt (Recent Filing)$5.79M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding56,425,282
10 Day Avg. Volume209,536
30 Day Avg. Volume323,402
Standard Deviation0.30
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.14
Forecast
1Y Price Target
$26.00Price Target Upside119.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Astria Therapeutics News
PremiumPre-Earnings
Is ATXS a Buy, Before Earnings?
Ownership Overview
11.96% Insiders
18.66% Mutual Funds
<0.01% Other Institutional Investors
59.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATXS FAQ
What was Astria Therapeutics’s price range in the past 12 months?
Astria Therapeutics lowest stock price was $4.26 and its highest was $16.90 in the past 12 months.
What is Astria Therapeutics’s market cap?
Currently, no data Available
When is Astria Therapeutics’s upcoming earnings report date?
Astria Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 116 days.
How were Astria Therapeutics’s earnings last quarter?
Currently, no data Available
Is Astria Therapeutics overvalued?
According to Wall Street analysts Astria Therapeutics’s price is currently Undervalued.
Does Astria Therapeutics pay dividends?
Astria Therapeutics does not currently pay dividends.
What is Astria Therapeutics’s EPS estimate?
Astria Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Astria Therapeutics have?
Astria Therapeutics has 56,425,280 shares outstanding.
What happened to Astria Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Astria Therapeutics?
Among the largest hedge funds holding Astria Therapeutics’s share is Perceptive Advisors LLC. It holds Astria Therapeutics’s shares valued at 59M.
---
Astria Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (119.97% Upside)
$26.00 (119.97% Upside)
Blogger Sentiment
Bearish
ATXS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 630.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
150.95%
12-Months-Change
Fundamentals
Return on Equity
-34.06%
Trailing 12-Months
Asset Growth
77.73%
Trailing 12-Months
Company Description
Astria Therapeutics
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.
---
ATXS Company Deck
---
ATXS Earnings Call
Q3 2023
0:00 / 0:00
---
ATXS Stock 12 Month Forecast
Average Price Target
$26.00
▲(119.97% Upside)
Technical Analysis
Seres Therapeutics
―
Fate Therapeutics
―
Voyager Therapeutics
―
Alaunos Therapeutics
―
Best Analysts Covering ATXS
1 Year
1 Year Success Rate
7/8 ratings generated profit
1 Year Average Return
+38.75%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +38.75% per trade.
---